Skip to content
drillr.ai

EQ

Equillium, Inc.

NASDAQ · USHealthcareBiotechnology
$2.47-4.63%

Price as of Jul 20, 2026

EQ news

Equillium, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 800,000 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee

    Globe Newswire ·

  2. EQ Inc. Delivers Profitable Fourth Quarter and 28% Sequential Revenue Growth in 2025 Year End Financial Results

    Integrated Rewards delivers record revenue with 91% sequential growth as Company achieves positive adjusted EBITDA for the quarter TORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / April 27, 2026 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data driven software and solutions, today announced its financial results for the fourth quarter and the year ended December 31, 2025. Revenue for the fourth quarter was $3.2 million, an increase of over 28% from Q3

    ACCESSWIRE ·

  3. Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNX4qv8Rw&default-theme=true LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcar

    Globe Newswire ·